Buy Signal on Argenx (ARGX-BE)
Argenx, a € 13.6 Bn market cap, is a Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system.
The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
ARGX-113 has been granted Orphan Drug Designation in both the U.S. and Europe for the treatment of myasthenia gravis (MG); MG is a disorder caused by an overactive immune system that attacks the proteins at the junctions of nerve and muscle cells, thereby impairing the communication signals and weakening the muscles.
The company just announced publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology which provided clinically meaningful improvements in strength and quality of life measures.
Argenx has a strong cash position of € 1.5bn. However it is burning cash, and its revenue is expected to reach € 170 M in 2021 coupled with a net loss of € -590m
Short term catalyst : Efgartigimod drug candidate.
This signal looks consistent with the European Biotechnology sector in Major Bullish Trend.